Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 19Colorectal Neoplasms 11Colonic Neoplasms 7Brain Neoplasms 6Rectal Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Thyroid Neoplasms 1Solid Tumor 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Multiple Myeloma 1Gliosarcoma 1Glioma 1Glioblastoma 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Astrocytoma 1Advanced BRAF Mutant Cancers 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × encorafenib × Clear all
NCT04526782 2025-11-18

ENCO-BRAF

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Active not recruiting
119 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡